Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697392 | 0.90 | LMNA (0.49) | TP53LMNAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL14697075 | 0.88 | SMN1; SMN2 (0.56) | TP53LMNAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL14697079 | 0.88 | L3MBTL1 (0.49) | TP53LMNAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL14697359 | 0.87 | L3MBTL1 (0.47) | TP53LMNAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL14697463 | 0.84 | PDE4B (0.43) | GRM1PDE4BPDE4D | |
| SCHEMBL13747380 | 0.81 | SMN1; SMN2 (0.60) | TP53LMNASMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL9670704 | 0.80 | HPGD (0.61) | TP53LMNAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL9670555 | 0.79 | NPC1 (0.58) | LMNAMAPTPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL14697173 | 0.76 | SMN1; SMN2 (0.40) | TP53MAPTSMN1; SMN2PDE4BPDE4D | |
| SCHEMBL5028783 | 0.75 | SMN1; SMN2 (0.66) | TP53LMNAPOLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611733-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE | 2017-05-25 | — | — | US | disclosed |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE | 2017-05-25 | — | — | US | disclosed |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE | 2017-05-25 | — | — | US | disclosed |
| US-9598402-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598402-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598402-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2744787-B1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RES INST (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2744787-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | Southern Research Institute (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013025508-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | HAVCR2, EIF2AK2, GLS2 | GRM1 522/4885TP53 2385/4885LMNA 2359/4885 |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | ZC3HAV1, EIF2AK2, GTF3C3 | GRM1 869/4885TP53 2756/4885LMNA 2862/4885 |
| US-10611733-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | ZC3HAV1, EIF2AK2, GTF3C3 | GRM1 869/4885TP53 2756/4885LMNA 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.